Atara Biotherapeutics remains eligible for $60M milestone payment

Atara remains eligible to receive a $60M milestone payment from Pierre Fabre upon FDA approval of the Ebvallo BLA, as well as significant double-digit tiered royalties as a percentage of net sales, and milestones related to commercial sales of Ebvallo. Atara remains committed to preserving this potential future value for all stockholders. If a strategic resolution is not reached to provide funding for its CAR-T development programs in Q1 2025, Atara intends to suspend all CAR-T activities, and significantly reduce company expenses and activities to only those that support the approval of Ebvallo, including through a near-term progressive transfer of all operational activities related to Ebvallo to Pierre Fabre. Atara has entered into a non-binding term sheet with Redmile Group to provide up to $15M in funding through an equity line of credit, which Atara believes is sufficient to fund the ongoing activities required to achieve BLA approval. Atara is also exploring alternative financing options, including non-dilutive sources of capital.